At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
Egg oral immunotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Desensitization to Egg With Subsequent Induction of Tolerance for Egg-Allergic Children (CoFAR 3)
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Apr 17, 2007·Updated Dec 13, 2017
In Brief
A Phase 2 clinical trial evaluating Egg oral immunotherapy and Control Group for Hypersensitivity and 2 related conditions. Completed, enrolled 55 participants across 5 sites.
Detailed Summary
The purpose of this study is to determine if oral immunotherapy (OIT) will desensitize a child with an allergy to egg and eventually lead to the development of tolerance to egg.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsConsortium of Food Allergy Research
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2007
Enrollment StartMay 2007
Primary CompletionDec 2010
Study CompletionDec 2013
TodayJul 2026
First PostedApr 17, 2007
Enrollment StartMay 1, 2007
Primary CompletionDec 1, 2010
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 19.2 years ago
Interventions
Egg oral immunotherapydrug
Egg white solid powder
Control Groupdrug
Placebo for egg white solid